4AZA2096

anti-inflammatory agent

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

1.	Colitis 08/01/2006 - "Anti-inflammatory activity of a pteridine derivative (4AZA2096) alleviates TNBS-induced colitis in mice." 08/01/2006 - "One synthetic pteridine analog (4AZA2096), shown to have strong inhibitory activity, was selected and tested for its efficacy to treat trinitrobenzenesulfonate (TNBS)-induced colitis in mice, a model of Crohn's disease. " 08/01/2006 - "In conclusion, we identified a pteridine derivative, 4AZA2096, with strong inhibitory activity on TNF production and a remission- inducing effect in TNBS colitis, supporting further preclinical and clinical development of this novel TNF inhibitor for treatment of inflammatory diseases."
2.	Edema (Dropsy) 08/01/2006 - "Colitic mice treated with 4AZA2096 orally (20 mg/kg/day) recovered more rapidly and, histologically, had a reduction of inflammatory lesions, less edema, a reduction of goblet cell loss, and reduced wall thickness. "
3.	Crohn Disease (Crohn's Disease) 08/01/2006 - "One synthetic pteridine analog (4AZA2096), shown to have strong inhibitory activity, was selected and tested for its efficacy to treat trinitrobenzenesulfonate (TNBS)-induced colitis in mice, a model of Crohn's disease. "

1.	Pteridines
2.	Tumor Necrosis Factor Inhibitors